Results of a Randomized, Placebo-Controlled, Phase 3 Trial of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty

Background

Moderate to severe acute pain is a prevalent condition in the US and managing this pain, especially in the postoperative setting, remains a challenge, in part due to
the limitation of existing treatment options like opioids to effectively manage pain without negative side effects, including issues of euphoria, dependence, misuse,
respiratory depression, and tolerability. The treatment challenges are further exacerbated by the apprehension of both clinicians and patients to use opioids. Cebranopadol is a first-in-class dual nociceptin/orphanin FQ peptide (NOP) and mu-opioid peptide (MOP) receptor (dual-NMR) agonist. This dual mechanism leads to potent analgesia while attenuating the negative side effects including euphoria, physical dependence, and respiratory depression of MOP agonism. This study evaluates the safety and efficacy of cebranopadol in managing acute post-operative pain following abdominoplasty.